Resource-stratified guidelines for the management of classical Hodgkin lymphoma

A visual abstract summarizing resource-stratified guidelines for the management of classical Hodgkin lymphoma. Existing...

Visual abstract | Key data from the phase I trial ELM-1, evaluating odronextamab in patients with CD20+ B-cell malignancies

The Lymphoma Hub is happy to present a visual abstract representing key...

Axi-cel vs SoC for R/R LBCL: ZUMA-7 primary analysis

The Lymphoma Hub is happy to present a Visual Abstract representing key data from the primary analysis of the phase III ZUMA-7 study (NCT03391466),...

TRANSFORM: Liso-cel vs SoC for second-line treatment of LBCL

Lisocabtagene maraleucel, a DC19-directed CAR T-cell therapy, vs SOC with salvage chemotherapy followed by ASCT as 2L treatments in...

CAR-T or stem cell transplant for second-line treatment of aggressive B-cell NHL?

Mehdi Hamadani explains the problems faced by high-risk patients and those who relapse early. He goes on to discuss...

How common are cardiotoxic events in patients receiving CD19 CAR T cells? What are the risk factors?

During the 4th European CAR T-Cell Meeting, the ALL Hub was pleased to speak with Daniel Chen,...

When is CAR-T a good option for patients with follicular and marginal zone lymphomas?

During the 4th European CAR T-cell Meeting, the Lymphoma Hub was pleased to speak with Gilles Salles, Memorial...

How might CAR T-cells change the treatment landscape for patients with CLL?

During the 4th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak with Julio Delgado, Hospital Clínic de...

Responses to the SARS-CoV-2 booster vaccination in patients with lymphoid malignancies

Here, we provide a summary of two papers investigating humoral and T-cell-mediated responses in patients with...

How do CAR T-cell recipients respond to COVID-19 vaccination?

During the 4th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak to Arnon Nagler, Sheba Medical Center, Tel Aviv, IL. We...

COVID-19 severity, mortality, and mRNA vaccine responses in patients with CLL

Since the first cases of coronavirus disease 2019 (COVID-19) were reported in December 2019, more than 3 million people...

Humoral and cellular responses in patients with lymphoid malignancies receiving SARS-Cov-2 vaccination

Factors that influence the efficacy of Severe Acute Respiratory Syndrome Coronavirus-2...